BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

904 related articles for article (PubMed ID: 19136393)

  • 1. Testicular function in poor-risk nonseminomatous germ cell tumors treated with methotrexate, paclitaxel, ifosfamide, and cisplatin combination chemotherapy.
    Pectasides D; Pectasides E; Papaxoinis G; Skondra M; Gerostathou M; Karageorgopoulou S; Kamposioras C; Tountas N; Koumarianou A; Psyrri A; Macheras A; Economopoulos T
    J Androl; 2009; 30(3):280-6. PubMed ID: 19136393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methotrexate, paclitaxel, ifosfamide, and cisplatin in poor-risk nonseminomatous germ cell tumors.
    Pectasides D; Pectasides E; Papaxoinis G; Xiros N; Kamposioras K; Tountas N; Economopoulos T
    Urol Oncol; 2010; 28(6):617-23. PubMed ID: 19110454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reproductive toxicity with and without LHRHA administration during adjuvant chemotherapy in patients with germ cell tumors.
    Kreuser ED; Hetzel WD; Hautmann R; Pfeiffer EF
    Horm Metab Res; 1990 Sep; 22(9):494-8. PubMed ID: 1701752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testicular function in patients with testicular cancer treated with bleomycin-etoposide-carboplatin (BEC(90)) combination chemotherapy.
    Pectasides D; Pectasides M; Farmakis D; Nikolaou M; Koumpou M; Kostopoulou V; Mylonakis N
    Eur Urol; 2004 Feb; 45(2):187-93. PubMed ID: 14734005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
    Hartmann JT; Gauler T; Metzner B; Gerl A; Casper J; Rick O; Horger M; Schleicher J; Derigs G; Mayer-Steinacker R; Beyer J; Kuczyk MA; Bokemeyer C;
    J Clin Oncol; 2007 Dec; 25(36):5742-7. PubMed ID: 18089869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel, ifosfamide, and nedaplatin (TIN) salvage chemotherapy for patients with advanced germ cell tumors.
    Nonomura N; Oka D; Nishimura K; Nakayama M; Inoue H; Mizutani Y; Miki T; Okuyama A
    Int J Urol; 2007 Jun; 14(6):527-31. PubMed ID: 17593098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.
    Tryakin A; Fedyanin M; Kanagavel D; Fainstein I; Sergeev J; Polockij B; Matveev V; Zakharova T; Garin A; Tjulandin S
    Urology; 2011 Sep; 78(3):620-5. PubMed ID: 21764427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporation of TIP (paclitaxel, ifosfamide, cisplatin) into first-line therapy for intermediate to poor risk testicular germ cell tumors with unfavorable marker decline after initial two cycles chemotherapy: a report of three cases.
    Ishioka J; Kageyama Y; Ichiyanagi N; Fukuda H; Higashi Y
    Int J Urol; 2007 May; 14(5):455-7. PubMed ID: 17511735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.
    Park S; Lee S; Lee J; Park SH; Park JO; Kang WK; Park YS; Lim HY
    Onkologie; 2011; 34(8-9):416-20. PubMed ID: 21934340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
    Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
    J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
    Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP;
    J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fertility and sexual function following orchiectomy and 2 cycles of chemotherapy for stage I high risk nonseminomatous germ cell cancer.
    Böhlen D; Burkhard FC; Mills R; Sonntag RW; Studer UE
    J Urol; 2001 Feb; 165(2):441-4. PubMed ID: 11176393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is high-dose chemotherapy after primary chemotherapy a therapeutic option for patients with primary mediastinal nonseminomatous germ cell tumor?
    Banna GL; De Giorgi U; Ferrari B; Castagna L; Alloisio M; Marangolo M; Rosti G; Santoro A
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1085-91. PubMed ID: 17084372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
    Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: a phase II study.
    Mardiak J; Sálek T; Sycová-Milá Z; Obertová J; Hlavatá Z; Mego M; Recková M; Koza I
    Neoplasma; 2005; 52(6):497-501. PubMed ID: 16284696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gonadal function of patients treated with cisplatin based chemotherapy for germ cell cancer.
    Brennemann W; Stoffel-Wagner B; Helmers A; Mezger J; Jäger N; Klingmüller D
    J Urol; 1997 Sep; 158(3 Pt 1):844-50. PubMed ID: 9258096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage chemotherapy with methotrexate, etoposide and actinomycin D in men with metastatic nonseminomatous germ cell tumors with a choriocarcinoma component: a preliminary report.
    Terakawa T; Miyake H; Muramaki M; Takenaka A; Fujisawa M
    Int J Urol; 2010 Oct; 17(10):881-5. PubMed ID: 20731738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract.
    Galsky MD; Iasonos A; Mironov S; Scattergood J; Donat SM; Bochner BH; Herr HW; Russo P; Boyle MG; Bajorin DF
    Urology; 2007 Feb; 69(2):255-9. PubMed ID: 17320659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis.
    Patel SR; Papadopolous N; Raymond AK; Donato M; Seong CM; Yasko AW; Lewis VO; Lin PP; Champlin R; Benjamin RS
    Cancer; 2004 Jul; 101(1):156-63. PubMed ID: 15222001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term fertility and Leydig cell function in patients treated for germ cell cancer with cisplatin, vinblastine, and bleomycin versus surveillance.
    Hansen SW; Berthelsen JG; von der Maase H
    J Clin Oncol; 1990 Oct; 8(10):1695-8. PubMed ID: 1698935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.